Heart disease caused by the loss or dysfunction of cardiomyocytes is the leading cause of death worldwide. The adult mammalian heart possesses little regenerative potential and therefore displays fatal loss of function following myocardial infarction (MI) and other heart diseases. Fibrosis and scar formation due to activation of cardiac fibroblasts serve as barriers to cardiac regeneration and contribute to loss of contractile function, pathological remodeling and susceptibility to arrhythmias. Recently, combinations of cardiogenic transcription factors were shown to be capable of activating cardiac gene expression in fibroblasts in vitro. Moreover, we have shown that forced expression of four transcription factors in cardiac fibroblasts is sufficient to activate cardiac gene expression in vivo, leading to improvement of cardiac function and reduction of adverse ventricular remodeling following MI in mice. Although these reprogramming processes are not yet optimized, they hold great potential for eventual cardiac repair, avoiding many of the obstacles associated with cellular transplantation. The overall goals of this project are to further define the mechanisms involved in reprogramming of cardiac cell fate and to optimize the technology for reprogramming of fibroblasts to cardiomyocytes in vivo as a strategy for cardiac repair. We will also assess the ability of selected small molecules and microRNAs to enhance cardiac reprogramming in vivo as a strategy for restoration of cardiac function following MI. These studies will provide important new insights into the mechanisms of cardiac cell fate specification and differentiation and will pave the way toward innovative approaches for cardiac repair.

Public Health Relevance

Ischemic heart disease resulting in myocardial infarction (MI) and heart failure is the leading cause of morbidity and mortality in the United States. Recent studies have suggested a new approach for restoration of cardiac function following MI, through conversion of cardiac fibroblasts into cardiomyocytes by the introduction of defined cardiac transcription factors. In this project, this approach will be optimized using combinations of cardiogenic transcription factors, small molecules and microRNAs and the cellular and molecular mechanisms underlying cardiac reprogramming in vitro and in vivo will be defined.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL077439-11
Application #
8676865
Study Section
Cardiovascular Differentiation and Development Study Section (CDD)
Program Officer
Schramm, Charlene A
Project Start
2004-07-01
Project End
2016-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
11
Fiscal Year
2014
Total Cost
$520,652
Indirect Cost
$193,198
Name
University of Texas Sw Medical Center Dallas
Department
Biochemistry
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Long, Chengzu; Li, Hui; Tiburcy, Malte et al. (2018) Correction of diverse muscular dystrophy mutations in human engineered heart muscle by single-site genome editing. Sci Adv 4:eaap9004
Amoasii, Leonela; Olson, Eric N; Bassel-Duby, Rhonda (2018) Control of Muscle Metabolism by the Mediator Complex. Cold Spring Harb Perspect Med 8:
Polster, Alexander; Nelson, Benjamin R; Papadopoulos, Symeon et al. (2018) Stac proteins associate with the critical domain for excitation-contraction coupling in the II-III loop of CaV1.1. J Gen Physiol 150:613-624
Liu, Ning; Garry, Glynnis A; Li, Stephen et al. (2017) A Twist2-dependent progenitor cell contributes to adult skeletal muscle. Nat Cell Biol 19:202-213
Moon, Jesung; Zhou, Huanyu; Zhang, Li-Shu et al. (2017) Blockade to pathological remodeling of infarcted heart tissue using a porcupine antagonist. Proc Natl Acad Sci U S A 114:1649-1654
Zhang, Yu; Long, Chengzu; Li, Hui et al. (2017) CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice. Sci Adv 3:e1602814
Baskin, Kedryn K; Makarewich, Catherine A; DeLeon, Susan M et al. (2017) MED12 regulates a transcriptional network of calcium-handling genes in the heart. JCI Insight 2:
Zhou, Huanyu; Morales, Maria Gabriela; Hashimoto, Hisayuki et al. (2017) ZNF281 enhances cardiac reprogramming by modulating cardiac and inflammatory gene expression. Genes Dev 31:1770-1783
Kyrychenko, Viktoriia; Kyrychenko, Sergii; Tiburcy, Malte et al. (2017) Functional correction of dystrophin actin binding domain mutations by genome editing. JCI Insight 2:
Amoasii, Leonela; Long, Chengzu; Li, Hui et al. (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med 9:

Showing the most recent 10 out of 94 publications